200 related articles for article (PubMed ID: 2180866)
1. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.
Cox JD; Pajak TF; Marcial VA; Hanks GE; Mohiuddin M; Fu KK; Byhardt RW; Rubin P
Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):515-21. PubMed ID: 2180866
[TBL] [Abstract][Full Text] [Related]
2. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.
Cox JD; Pajak TF; Marcial VA; Coia L; Mohiuddin M; Fu KK; Selim H; Rubin P; Ortiz H
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1191-5. PubMed ID: 2045293
[TBL] [Abstract][Full Text] [Related]
3. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.
Rosenthal DI; Mohamed ASR; Garden AS; Morrison WH; El-Naggar AK; Kamal M; Weber RS; Fuller CD; Peters LJ
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1002-1011. PubMed ID: 28721881
[TBL] [Abstract][Full Text] [Related]
4. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules.
Garden AS; Morrison WH; Ang KK; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):493-502. PubMed ID: 7852111
[TBL] [Abstract][Full Text] [Related]
5. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313.
Cox JD; Pajak TF; Marcial VA; Coia L; Mohiuddin M; Fu KK; Selim HM; Byhardt RW; Rubin P; Ortiz HG
Cancer; 1992 Jun; 69(11):2744-8. PubMed ID: 1571904
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the Hammersmith (1971-75) and Edinburgh (1977-82) neutron therapy trials of certain cancers of the oral cavity, oropharynx, larynx and hypopharynx. Medical Research Council Neutron Therapy Working Group.
Br J Radiol; 1986 May; 59(701):429-40. PubMed ID: 3518846
[TBL] [Abstract][Full Text] [Related]
7. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.
Krstevska V; Crvenkova S
Croat Med J; 2006 Feb; 47(1):42-52. PubMed ID: 16489696
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of different variants of hyperfractionated irradiation in cancer of the naso- and oropharynx and of the oral mucosa].
Aliev BM; Chuprik-Malinovskaia TP; Aleknavichius EE
Med Radiol (Mosk); 1988 Jun; 33(6):37-41. PubMed ID: 3386429
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial.
Peters LJ; Goepfert H; Ang KK; Byers RM; Maor MH; Guillamondegui O; Morrison WH; Weber RS; Garden AS; Frankenthaler RA
Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):3-11. PubMed ID: 8482629
[TBL] [Abstract][Full Text] [Related]
10. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
Sanguineti G; Richetti A; Bignardi M; Corvo' R; Gabriele P; Sormani MP; Antognoni P
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):762-71. PubMed ID: 15708255
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate and radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, oropharynx, supraglottic larynx, and hypopharynx. (Preliminary report of a controlled clinical trial of the Radiation Therapy Oncology Group).
Kramer S
Can J Otolaryngol; 1975; 4(2):213-8. PubMed ID: 1139418
[No Abstract] [Full Text] [Related]
12. Hyperfractionated radiation therapy for hypopharyngeal carcinoma compared with conventional radiation therapy: local control, laryngeal preservation and overall survival.
Niibe Y; Karasawa K; Mitsuhashi T; Tanaka Y
Jpn J Clin Oncol; 2003 Sep; 33(9):450-5. PubMed ID: 14594938
[TBL] [Abstract][Full Text] [Related]
13. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
14. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
[TBL] [Abstract][Full Text] [Related]
15. [Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas].
Stuschke M; Budach V; Dinges S; Jahnke K; Budach W; Heselmann I; Unger A; Stüben G; Sack H
Strahlenther Onkol; 1994 Dec; 170(12):689-99. PubMed ID: 7817270
[TBL] [Abstract][Full Text] [Related]
16. Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics--a phase II multicenter study.
Antognoni P; Bignardi M; Cazzaniga LF; Poli AM; Richetti A; Bossi A; Rampello G; Barbera F; Soatti C; Bardelli D; Giordano M; Danova M
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1137-45. PubMed ID: 8985036
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
[TBL] [Abstract][Full Text] [Related]
18. [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
Rubio Suárez A; Teigeiro Núñez V; Gallo Terán J; Señaris González B; Mesuro Domínguez N
Acta Otorrinolaringol Esp; 2003 Dec; 54(10):697-703. PubMed ID: 15164709
[TBL] [Abstract][Full Text] [Related]
19. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
20. The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract.
Pfreundner L; Willner J; Marx A; Hoppe F; Beckmann G; Flentje M
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1287-97. PubMed ID: 10889383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
